` OPTN (OptiNose Inc) vs S&P 500 Comparison - Alpha Spread

OPTN
vs
S&P 500

Over the past 12 months, OPTN has underperformed S&P 500, delivering a return of -31% compared to the S&P 500's +13% growth.

Stocks Performance
OPTN vs S&P 500

Loading
OPTN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
OPTN vs S&P 500

Loading
OPTN
S&P 500
Difference
www.alphaspread.com

Performance By Year
OPTN vs S&P 500

Loading
OPTN
S&P 500
Add Stock

Competitors Performance
OptiNose Inc vs Peers

OptiNose Inc
Glance View

Market Cap
96.6m USD
Industry
Pharmaceuticals

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.

OPTN Intrinsic Value
19.96 USD
Undervaluation 52%
Intrinsic Value
Price
Back to Top